- Home
- ASIX vs MYGN Comparison
ASIX vs MYGN Comparison
Compare ASIX & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASIX
- MYGN
- Stock Information
- Founded
- ASIX 2016
- MYGN 1991
- Country
- ASIX United States
- MYGN United States
- Employees
- ASIX N/A
- MYGN N/A
- Industry
- ASIX Major Chemicals
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ASIX Industrials
- MYGN Health Care
- Exchange
- ASIX Nasdaq
- MYGN Nasdaq
- Market Cap
- ASIX 654.2M
- MYGN 744.7M
- IPO Year
- ASIX N/A
- MYGN 1995
- Fundamental
- Price
- ASIX $23.12
- MYGN $5.34
- Analyst Decision
- ASIX Buy
- MYGN Hold
- Analyst Count
- ASIX 1
- MYGN 15
- Target Price
- ASIX $32.00
- MYGN $15.14
- AVG Volume (30 Days)
- ASIX 180.9K
- MYGN 1.3M
- Earning Date
- ASIX 08-01-2025
- MYGN 08-05-2025
- Dividend Yield
- ASIX 2.77%
- MYGN N/A
- EPS Growth
- ASIX 3682.26
- MYGN N/A
- EPS
- ASIX 3.11
- MYGN N/A
- Revenue
- ASIX $1,558,519,000.00
- MYGN $831,300,000.00
- Revenue This Year
- ASIX $7.41
- MYGN N/A
- Revenue Next Year
- ASIX $4.60
- MYGN $6.68
- P/E Ratio
- ASIX $7.57
- MYGN N/A
- Revenue Growth
- ASIX 6.03
- MYGN 7.38
- 52 Week Low
- ASIX $18.44
- MYGN $3.81
- 52 Week High
- ASIX $33.00
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- ASIX 41.77
- MYGN 50.85
- Support Level
- ASIX $24.37
- MYGN $4.90
- Resistance Level
- ASIX $25.53
- MYGN $5.83
- Average True Range (ATR)
- ASIX 0.70
- MYGN 0.28
- MACD
- ASIX -0.12
- MYGN 0.04
- Stochastic Oscillator
- ASIX 17.18
- MYGN 54.21
About ASIX AdvanSix Inc.
AdvanSix Inc. is a diversified chemistry company playing a critical role in globally supply chains, innovating and delivering essential products for customers in a wide variety of end markets and applications that touch people's lives, such as building and construction, fertilizers, agrochemicals, plastics, solvents, packaging, paints, coatings, adhesives and electronics. The company key products includes: Nylon, Caprolactam, Plant Nutrients, and Chemical Intermediates The majority of sales is from Plant Nutrients products.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.